All Oncology News

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.

Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.

Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.

Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.

GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.

Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.

A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.

A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.

MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.

T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.

During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.

R. Lor Randall, MD, FACS, discusses novel precision surgery techniques that are making progress in sarcoma care.

Aaron Gerds, MD, outlines how cytopenias affect patients with myelofibrosis and how these can help drive JAK inhibitor selection.

The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.